Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria, tetanus, pertussis, and poliomyelitis vaccine
- Development stage
- Unknown
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
DPT-IPV (TETRABIK) is a quadrivalent combination vaccine developed by Mitsubishi Tanabe Pharma Corporation in collaboration with the Research Foundation for Microbial Diseases of Osaka University (BIKEN). It is indicated for the prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children. The vaccine formulation includes diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxin [PT] and filamentous hemagglutinin [FHA]), and inactivated poliovirus (IPV antigen, Sabin strain). Approved in Japan in 2012, it is administered via subcutaneous injection and is a standard component of the Japanese pediatric immunization schedule. In clinical development, it has served as an active control in Phase 3 trials for pentavalent vaccines (such as BK1310) that add a Haemophilus influenzae type b (Hib) component.
- Brand names
- TETRABIK
- Other names
- DPT-IPVDTaP-IPVDPT-sIPV
02
Targets
Diphtheria toxinBordetella pertussis protective antigens
Beyond the preview
Go deeper on diphtheria, tetanus, pertussis, and poliomyelitis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria, tetanus, pertussis, and poliomyelitis vaccine.